PC
TAK icon

PointState Capital’s Takeda Pharmaceutical TAK Stock Holding History

PointState Capital’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-73,600
Closed -$1.24M – 149
2018
Q4 		$1.24M Buy
+73,600
New +$1.24M 0.05% 70

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PointState Capital's TAK Position: Q1 2019 in Review

PointState Capital sold out of Takeda Pharmaceutical (TAK) in Q1 2019, closing a stake of 73,600 shares — an estimated $1.24M sold.

PointState Capital first reported a position in TAK in Q4 2018 and held it in 1 quarter. The position peaked at $1.24M in Q4 2018. 390 funds tracked by Wall St. Rank hold TAK as of Q1 2019.

  • PointState Capital reported no remaining Takeda Pharmaceutical position as of Q1 2019 after selling out during the quarter.
  • PointState Capital sold 73,600 Takeda Pharmaceutical shares in Q1 2019, an estimated $1.24M.
  • PointState Capital first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 1 quarter.
  • PointState Capital's Takeda Pharmaceutical position peaked at $1.24M in Q4 2018.
  • 390 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2019.

Based on PointState Capital's 13F filing for Q1 2019, filed 15 May 2019.